Boots (company) Launches In-Store Weight Loss Drug Service
Analysis based on 8 articles · First reported Feb 13, 2026 · Last updated Feb 13, 2026
The launch of Walgreens Boots Alliance===Boots (company)'s in-store weight loss drug service is expected to positively impact the pharmaceutical and retail sectors by increasing accessibility to treatments like Tirzepatide and Semaglutide. This move could boost sales for Walgreens Boots Alliance===Boots (company), Eli Lilly and Company, and Novo Nordisk, reflecting a growing demand for weight management solutions.
Walgreens Boots Alliance===Boots (company) has launched a trial in-store service across 17 locations nationwide, including London, Manchester, and Edinburgh, offering weight loss drugs such as Tirzepatide (made by Eli Lilly and Company) and Semaglutide (made by Novo Nordisk) for the first time on the high street. Customers can receive an in-person consultation with a pharmacist to assess eligibility, a departure from the previous online-only prescription model for these medications. While the United Kingdom===National Health Service in England allows GPs to prescribe Tirzepatide to severely obese individuals with other health issues, this new service by Walgreens Boots Alliance===Boots (company) aims to provide more convenient access to a broader segment of the population in the United Kingdom, where over 1.5 million people are already estimated to be taking weight loss drugs.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard